Company Overview
Phio Pharmaceuticals Corp. operates as a clinical stage biopharmaceutical entity dedicated to the development of immuno-oncology therapeutics within the United States. The company focuses on creating innovative treatments, specifically engineering PH-762, an INTASYL compound designed to lower PD-1 expression levels during ongoing multi-center Phase 1b dose-escalating clinical trials, alongside other assets like PH-894. This organization functions within the broader healthcare sector and specifically the biotechnology industry, fields characterized by high research intensity and significant capital requirements to bring novel drugs to market. The company currently maintains a market capitalization of $14.64M and employs a workforce of 6 individuals, indicating a very early-stage operational scale typical of entities in the clinical development phase. These valuation and personnel figures suggest that Phio is a micro-cap entity with limited market penetration and revenue generation capabilities, positioning it as a high-risk, high-potential investment vehicle where the primary value driver remains future clinical trial success rather than current profitability or established market share.
Financial Health
The company reports no revenue for the trailing twelve months, a net income of $-8,698,000, and an EBITDA of $-9,217,000, reflecting a financial structure entirely driven by research and development expenditures rather than commercial sales. The substantial gap between zero revenue and negative net income reveals a cost structure dominated by operational burn rates associated with clinical trial management and scientific staffing, which is standard for biotechnology firms pre-revenue. Free cash flow stands at $-5,056,500, indicating that the company is consuming cash reserves to fund its operations and does not yet generate self-sustaining liquidity from its business activities. Despite these outflows, the balance sheet demonstrates a conservative stance with $21.03M in cash on hand against no recorded debt, providing a significant buffer to support ongoing clinical programs without the pressure of mandatory interest payments. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is expected for a company with no sales but highlights the lack of a traditional cost-of-goods-sold or operating leverage mechanism at this stage of development. The current ratio is an exceptionally high 16.03, suggesting that the company holds a vast amount of liquid assets relative to its current liabilities, providing ample short-term liquidity to weather extended periods of cash burn. Return on Equity is -69.9% and Return on Assets is -42.3%, metrics that indicate the company is currently destroying shareholder and asset value through its investment in clinical research, a necessary but costly characteristic of early-stage biotech development where management effectiveness is measured by capital allocation efficiency rather than return generation.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the absence of earnings, while the forward P/E is listed as -2.03, a negative figure that implies the market is valuing the company based on future potential earnings rather than current performance expectations. The price-to-book ratio is 0.73, indicating that the market values the company at a discount to its book value, a common valuation characteristic for distressed or pre-revenue biotechnology firms where tangible assets do not fully capture the value of intellectual property and pipeline potential. The price-to-sales ratio is N/A and the EV/EBITDA is 0.69, suggesting that traditional sales-based or cash-flow-based valuation multiples are not applicable given the lack of commercial revenue, forcing reliance on asset-light or clinical-stage metrics for comparison. The stock has traded between a 52-week high of $4.19 and a 52-week low of $0.81, and without a specific current price listed in the facts, the valuation range defines the volatility envelope within which the security has moved over the last year. The beta of 0.91 indicates that the stock's price volatility is roughly in line with the broader market, suggesting that despite its high-risk nature as a small-cap biotech, its systematic risk exposure is moderate relative to the overall market index.
Growth & Income
Revenue growth and earnings growth rates are both N/A, as the company has not yet generated commercial sales to establish a historical growth trajectory or earnings expansion. Since the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, instead reinvesting all available resources and cash reserves directly into the advancement of its immuno-oncology therapeutic pipeline and clinical trial infrastructure. The overall growth and income profile is defined by a complete reliance on capital markets for funding and a reinvestment strategy focused on achieving clinical milestones rather than generating immediate cash returns or shareholder distributions. This profile is typical for clinical stage companies where the primary objective is to extend the life of the business and advance assets into later-stage trials rather than to provide current income or demonstrate revenue scale.